Phase II trial of OHR/AVR118 (Ohr Pharmaceutical) shows some benefits for cancer patients with Cachexia

Results of a Phase II trial to evaluate the effects of OHR/AVR118, from Ohr Pharmaceutical, in advanced Cancer patients with Cachexia, show the drug offers some benefits. Eighteen patients, three with stage III and fifteen with stage IV cancers completed the treatment protocol. While the primary trial end point of weight gain was not achieved, at the completion of treatment, patients achieved stabilization of body weight, body fat and muscle mass with a significant increase in appetite (p=.001).

Moreover, Patient Generated Subjective Global Assessment scores demonstrated improvement (p=.025), indicating an enhanced quality of life. No statistically significant differences from baseline were observed in body fat content, arm circumference, triceps fold measurement, nausea or vomiting. In an extension, sustained body weight stabilization was maintained even on prolonged therapy with the drug in this sub-group of patients. This was despite the fact that 7 of the 18 patients were on chemotherapy, and 1 on radiotherapy, during the period.